A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Peritoneal Carcinomatosis

Interventions

BIOLOGICAL

GL-ONC1

A genetically-engineered vaccinia virus administered via intraperitoneal infusion through an indwelling catheter every 4 weeks for 4 cycles.

Trial Locations (1)

University Hospital Tuebingen, Tübingen